Our data demonstrated that CKD-L, a selective HDAC6 inhibitor, decreased the arthritis score and protected against joint destruction in the CIA model, and reduced the expressions of TNF and IL-1β, and increased the expression of IL-10 in PBMC from RA patients. This evidence concerns the gene HDAC6 and rheumatoid arthritis.